Brussels, Belgium, February 28, 2013

Corporate finance advisor Merodis is proud to announce that it successfully executed the sale of the Arterin business on behalf of Pharco ( to Omega Pharma ( The overall transaction value amounts to EUR 10m + existing inventory, paid in cash to the seller.

Founded in 2003, Pharco is developing and commercializing OTC (Over-The-Counter) products in the field of nutritherapy and phytotherapy. Pharco is listed on Euronext under the ISIN: BE0003835528. Its Arterin business is Belgium-leading cholesterol-related food supplement sold in pharmacies. Arterin contains red yeast rice which has scientifically-proven beneficial effects on the level of cholesterol. Launched in 2006 in Belgium and 2008 in France, Arterin has rapidly grown to be a key product in Pharco’s portfolio.

As part of the transaction, Pharco is transferring to Omega Pharma, one of the European leading specialists in OTC medecines and healthcare products, all assets related to its Arterin business as well as its team of sales representatives associated with the product.

The Merodis transaction team was led by Dirk Marckx and Rodolphe Blondiau.

Karel Goderis, managing director of Pharco, said: “On top of Merodis’ solid corporate finance expertise, we truly appreciated the team’s life sciences and profound OTC/pharma sector knowledge alongside their numerous contacts within the industry”.